Found 298 clinical trials
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
- 0 views
- 19 Feb, 2024
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …
- 0 views
- 19 Feb, 2024
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.
- 0 views
- 19 Feb, 2024
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer
Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.
- 4 views
- 19 Feb, 2024
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
- 0 views
- 19 Feb, 2024
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and international guidelines for the diagnosis of patients with biochemical recurrence of prostate cancer.
- 0 views
- 19 Feb, 2024
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …
- 0 views
- 19 Feb, 2024
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, …
- 0 views
- 19 Feb, 2024
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer
In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: Implantation …
- 2 views
- 19 Feb, 2024
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or …
- 0 views
- 19 Feb, 2024